Join the Tirzepatide group to help and get support from people like you.
Tirzepatide News
Rival GLP-1 Weight-Loss Drug, Ecnoglutide, Emerges From China
TUESDAY, June 24, 2025 — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to blockbuster drugs Ozempic/Wegovy and Zepbound, clinical trial results show. Ecnoglutide helped p...
Few Adolescents With Obesity Prescribed Obesity Medications
FRIDAY, June 13, 2025 – Despite an increase in the prevalence of prescribing, only 0.5 percent of U.S. adolescents with obesity were prescribed an obesity medication in 2023, according to research...
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 – For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower than the percentages...
Real-World Results For GLP-1 Drugs Underwhelm, Study Says
WEDNESDAY, June 11, 2025 — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised by the drugs’ clinical trials, a new study says....
American Society of Clinical Oncology, May 31-June 3
The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more than 35,000 participants, including clinicians, academicians, allied health p...
Doctors Favor CPAP, Patients Favor Tirzepatide for Comorbid Obesity, Sleep Apnea
MONDAY, June 9, 2025 – Both continuous positive airway pressure (CPAP) and tirzepatide are acceptable treatments for comorbid obesity and obstructive sleep apnea (COBOSA), with providers favoring...
CPAP Or Zepbound? Patients, Doctors Debate Sleep Apnea Treatment
MONDAY, June 9, 2025 — A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study reports. Doctors favor treatment with continuous p...
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 – For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with...
Weight-Loss Drugs May Lower Risk Of Obesity-Related Cancers
WEDNESDAY, May 28, 2025 — Popular GLP-1 weight loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a new study says. People taking a ...
FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs
FRIDAY, May 23, 2025 — A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on. The U.S. Food and Drug A...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 – For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric...
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 – Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and...
Tirzepatide Dispensations Increased Rapidly After Approval
TUESDAY, April 15, 2025 – After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without...
ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM
FRIDAY, April 4, 2025 – For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and...
Tirzepatide, Semaglutide Not Cost-Effective at Current Prices
WEDNESDAY, March 19, 2025 – Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online March 14 in JAMA Health Forum. Jennifer H....
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome, Diabetes, Type 2